Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
124I-F8IL10 targeting study in rheumatoid arthritis
NL-OMON28317Recruiting
- Sponsor
- VU University Medical Center
- Start
- May 2013
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of 124I-F8IL10 in rheumatoid arthritis (RA), sponsored by VU University Medical Center. Primary endpoints: Targeting performance of 124I-F8IL10 and Pharmacokinetics and pharmacodynamics of 124I-F8IL10. Started May 2013; status: recruiting.
02
Drugs
124I-F8IL10
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON28317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON28317.